Therapies that inhibit JAK1 and JAK2 catalytic activities have been designed and developed in response to the discovery of dysregulated JAK-STAT signaling in MPN patients, regardless of the source(s) of this dysregulated activity. This evidence concerns the gene JAK1 and myeloproliferative neoplasm.